Celcuity Inc. (NASDAQ:CELC)
| Market Cap | $2.61B-47.3% |
| Revenue (ttm) | $0 |
| Net Income | -$256.01M-57.3% |
| EPS | -$4.70-28.1% |
| Shares Out | 48.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 636,527 |
| Open | $55.02 |
| Previous Close | $56.31 |
| Day's Range | $53.22 - $57.00 |
| 52-Week Range | $53.20 - $151.02 |
| Beta | 0.16 |
| Analysts | Buy |
| Price Target | $160.67(+201.16%) |
| Earnings Date | Mar 24, 2027 |
About CELC
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
4 firms rating CELC in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 24, 2027Earnings report
$CELC stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of CELC by members of U.S. Congress
| Tom MalinowskiHouse | Sale$1.00K – $15.00K | May 26, 2021 |
| Tom MalinowskiHouse | Purchase$1.00K – $15.00K | Jun 18, 2020 |
Recently reported changes in CELC holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CELC's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CELC Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CELC patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CELC from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CELC
| VTIVanguard Morningstar Total Stock Market ETF | $76.52M |
| XBIState Street SPDR S&P Biotech ETF | $69.09M |
| IWMiShares Russell 2000 ETF | $56.60M |
| VXFVanguard Extended Market ETF | $32.34M |
| IWOiShares Russell 2000 Growth ETF | $20.47M |
| VTWOVanguard Russell 2000 ETF | $15.64M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CELC’s recent data — informational, not investment advice
What’s Behind the Score
News check: FDA acceptance of supplemental application for breast cancer indication represents concrete regulatory progress with meaningful clinical potential.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| CANC | Tema Oncology ETF | 1.38% |
| SGRW | Harbor Active Small Cap Growth ETF (SGRW) | 0.94% |
| XBI | State Street SPDR S&P Biotech ETF | 0.78% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.54% |
| TDNA | T. Rowe Price Biotech ETF | 0.49% |
| HELX | Franklin Genomic Advancements ETF | 0.33% |
| ACSG | American Century Small Cap Growth Insights ETF | 0.32% |
| VTWG | Vanguard Russell 2000 Growth ETF | 0.20% |
| SSMG | Virtus Silvant Small/Mid Growth ETF | 0.17% |
| IWO | iShares Russell 2000 Growth ETF | 0.16% |
| PWS | Pacer WealthShield ETF | 0.15% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.15% |
Weight is the stock’s share of each fund’s holdings.
